<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Allegation</title>
	<atom:link href="http://www.tapanray.in/tag/allegation/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Should ‘Pharma Marketing’ Be In The Line of Fire?</title>
		<link>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-marketing-be-in-the-line-of-fire</link>
		<comments>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/#comments</comments>
		<pubDate>Sun, 26 Nov 2017 23:31:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['condo']]></category>
		<category><![CDATA[ails]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[serious]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8570</guid>
		<description><![CDATA[Close to half a century ago, Peter Drucker &#8211; the Management Guru wrote: As the purpose of business is to create customers, any business enterprise has two basic functions: marketing and innovation. Drucker’s concept is so fundamental in nature that it will possibly never change, ever. That innovation &#8230; <a href="http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Allegation of ‘Marketing Malpractices’ in the pharmaceutical Industry of India has assumed a huge proportion– who will ‘bell the cat’?</title>
		<link>http://www.tapanray.in/allegation-of-marketing-malpractices-in-the-pharmaceutical-industry-of-india-has-assumed-a-huge-proportion-who-will-bell-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=allegation-of-marketing-malpractices-in-the-pharmaceutical-industry-of-india-has-assumed-a-huge-proportion-who-will-bell-the-cat</link>
		<comments>http://www.tapanray.in/allegation-of-marketing-malpractices-in-the-pharmaceutical-industry-of-india-has-assumed-a-huge-proportion-who-will-bell-the-cat/#comments</comments>
		<pubDate>Thu, 19 Mar 2009 01:30:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[assumed]]></category>
		<category><![CDATA[bell]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[huge]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[proportion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=938</guid>
		<description><![CDATA[Sometime back, in its January – March, 2004 issue, ‘Indian Journal of Medical Ethics’ (IJME)in context of marketing practices for ethical pharmaceutical products in India commented:“If the one who decides, does not pay and the one who pays, does not &#8230; <a href="http://www.tapanray.in/allegation-of-marketing-malpractices-in-the-pharmaceutical-industry-of-india-has-assumed-a-huge-proportion-who-will-bell-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/allegation-of-marketing-malpractices-in-the-pharmaceutical-industry-of-india-has-assumed-a-huge-proportion-who-will-bell-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
